查詢結果分析
相關文獻
- Treatment of Metastatic Colorectal Adenocarcinoma with Fluorouracil and High-Dose Leucovorin : A Pilot Study
- Oxaliplatin in Combination with 5-Fluorouracil and Leucovorin as Second-Line Therapy for Metastatic Colorectal Cancer
- Regorafenib:轉移性大腸直腸癌與胃腸道基質瘤之口服標靶藥物
- Efficacy and Safety of Two Different Regimens of Irinotecan for Metastatic Colorectal Cancer: Experience in a Southern Taiwan Medical Center
- Hepatitis B and/or Hepatitis C Infection Does Not Influence Survival Rate among Patients with Metastatic Colorectal Cancer
- Gastrointestinal Perforation in Patients with Metastatic Colorectal Cancer Treated with Bevacizumab (Avastin)--Three Cases Report
- Perforated Duodenal Ulcer with Blurred Peritonitis in a Colorectal Cancer Patient with Liver Metastasis
- Oxaliplatin/5-Fluorouracil/Leucovorin (FOLFOX4) in Metastatic Colorectal Cancer (CRC)
- Weekly Low Dose Irinotecan Combined with Oral Tegafur-Uracil Plus Leucovorin as an Out Patient Treatment in Patients with Metastatic Colorectal Cancer (CRC)
- Decreasing Dosage of Irinotecan, 5-Flurouracil (5-FU) and Leucovorin (LV) in the Treatment of Advanced and /or Metastatic Colorectal Cancer: A Phase Ⅱ Study
頁籤選單縮合
題名 | Oxaliplatin/5-Fluorouracil/Leucovorin (FOLFOX4) in Metastatic Colorectal Cancer (CRC)=Oxaliplatin/5-Fluorouracil/Leucovorin (FOLFOX4)於轉移性大腸直腸癌(CRC)之使用 |
---|---|
作者姓名(中文) | 馬政仁; 謝建勳; 陳芳銘; 陳漢文; 黃哲人; 黃宗人; 王照元; | 書刊名 | 中華民國大腸直腸外科醫學會雜誌 |
卷期 | 18:3 2007.09[民96.09] |
頁次 | 頁65-72 |
分類號 | 416.245 |
關鍵詞 | 轉移性大腸直腸癌; Oxaliplatin; Metastatic colorectal cancer; |
語文 | 英文(English) |
英文摘要 | Purpose: In studies of Western countries, oxaliplatin/5-fluorouracil/ leucovorin (FOLFOX4) has been shown to be an effective and well-tolerated regimen for patients with metastatic colorectal cancer. However, the toxicity profile and efficacy of FOLFOX4 in the Taiwanese population may be different from that of Caucasians. This study evaluates the toxicities of FOLFOX4 and the objective response rate achieved in our patients with metastatic colorectal cancer. Methods: Forty patients with metastatic colorectal cancer managed with FOLFOX4 between January 2005 and April 2006 in Kaohsiung Medical University Hospital were analyzed retrospectively. Toxicities were regularly recorded by the National Cancer Institute common toxicity system and tumor responses were assessed radiologically with a computed tomographic (CT) scan every four cycles, according to the Response Evaluation Criteria in Solid Tumors (RECIST). Results: Of all toxicities recorded, grade 1 hypersensitivity was found with a rate of 20% (8/40). The rate of sensory neuropathy encountered was 40% (16/40), mainly grade 2 (11/40). Among 16 patients with neuropathy, two (5%) had grade 3 paresthesia, which did not resolve after FOLFOX4 had been discontinued for over half-a-year. There was no pharyngo-laryngeal dysesthesia observed. Gastrointestinal adverse effects were mild to moderate and few of them needed intravenous hydration therapy. The overall response rate (all partial responses) was 45% (18/40) and the stable disease rate was 20% (8/40). Six patients (15%) died in the therapeutic period but none of their deaths was due to toxicities. Conclusions: FOLFOX4 is a favorable effective regimen coupled with an acceptable safety profile for metastatic colorectal cancer among Taiwanese. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。